Loading...
Market
What will be the change in the number of new prescriptions for Ozempic and Wegovy in Q3 2024?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Prescription data from pharmaceutical industry reports
Story
Harvard Study Links Ozempic, Wegovy to 6.7% Risk of Serious Eye Condition
Jul 3, 2024, 03:39 PM
A new study by Massachusetts Eye and Ear and Harvard has revealed a potential link between Novo Nordisk’s GLP-1 drugs, Ozempic and Wegovy, and a serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss. The study, published in JAMA Ophthalmology, found that patients prescribed these drugs for diabetes or weight loss had a higher risk of developing NAION compared to those not on the medication. The risk of optic neuropathy was 6.7% for the Ozempic group and 0.8% for the control group at 36 months. This is the first report of such an association, based on a matched cohort of approximately 17,000 individuals, highlighting the need for further research to understand the safety implications of these widely used medications.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Below 50,000 • 25%
50,000 to 100,000 • 25%
100,000 to 150,000 • 25%
Above 150,000 • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Yes • 50%
No • 50%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Price reductions • 25%
Price increases • 25%
No change • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Zepbound gains >10% market share over Wegovy • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Wegovy gains market share over Zepbound • 25%